Biopharm GmbH
BIOPHARM is one of the pioneers in the research and development of biologics. Our platform technology of recombinant
human growth factors combines our expertise and experience of more than 30 years with innovative applications in the
field of orthopedics, dermatology and personalized medicine. BIOPHARM successfully achieved Proof of Concept for all
indications and is now out-licensing the product pipeline for further clinical development and commercialization.
Mission
Our mission is driven by our company philosophy of constant innovation. Combining our expertise and experience of more than 30 years in Biotechnology BIOPHARM is devoted to discovering innovative substances and technologies in Regenerative Medicine. As a privately-owned company we strive to maintain independence and flexibility. Our core values are committed to improve human life, achieve scientific excellence and operate with the highest standards of integrity to meet the changing needs of the health
care market worldwide.
Management
Michael Paulista – Managing Director
Michael founded Biopharm 1986 in the growing biotech ecosystem of Heidelberg, Germany. Since, he has succeeded to create a Growth Factor Platform Technology around the proprietary growth factor GDF-5. He has developed several partnerships and licenses with big pharma companies.
Osteoarthritis
One of the few genes associated with osteoarthritis is the Growth and Differentiation Factor 5 (GDF5), a protein of the Bone Morphogenetic Protein (BMP) family. Biopharm GmbH has developed the highly effective variant R399E, a single point mutation of GDF5. Preclinical osteoarthritis development performed by Merck KGaA exhibits a unique combination of anabolic, anti-catabolic, anti-inflammatory and pain-reducing properties for R399E.
Currently, Biopharm GmbH owns all rights on R399E after the decision of Merck KGaA to exit osteoarthritis development focusing now on other strategic indications. This creates the unique opportunity to invest into a phase 1 ready, “pharma-grade” development candidate. R399E has the chance to become a prominent acquisition target for pharma companies to enter financially attractive osteoarthritis market.
History
-
Integrating the analytical services for the pharmaceutical and biotechnological industries in Symbiosis GmbH
-
Biopharm GmbH moved from Heidelberg to Eppelheim.
-
Clear effects of Biopharm's growth factor and it's mutants shown in the following areas: Parkinson's disease, Erectile Dysfunction and peripheral nervous system. Proof of Concept (POC) for all indications succesfully achieved.
-
Cooperation with Merck Serono in research directed toward the molecular engineering of a biologic compound for the treatment of osteoarthritis.
-
New project in the field of osteoporosis in cooperation with Jena University and funded by the German Ministry of Education and Research
-
Submission of IDE (Phase III) for MD05-P by Medtronic, Inc. (Scil Technology GmbH)
-
Exclusive Research Cooperation with Prof. Dr. Dr. Detlef Schuppan (Harvard University/Mainz University) in Personalized Medicine
-
Exclusive Research Cooperation with Freudenberg (Weinheim) for Advanced Wound Care
-
International sub-license for rhGDF-5 in oral, maxillary and facial surgery to Medtronic, Inc.
-
Start of the multicenter clinical trial for the indication "Spinal Fusion" in the USA
-
International license for rhGDF-5 in orthopedics to DePuy Spine, Johnson & Johnson
-
International license for rhGDF-5 in oral, maxillary and facial surgery to Scil Technology GmbH
-
Occupation of second building with more than 1500 qm of modern laboratory and office space in Eppelheim near Heidelberg
-
35 employees, start of work on the development of biogenerics and bioassays for products for important therapeutic indications
-
First international cooperation with a large industrial partner for the development of rhGDF-5
-
First GLP certification
-
International patents for rhGDF-5 and MP121
-
15 employees, well established contract analysis and internal research
-
Biopharm founded by Michael Paulista in Heidelberg
